AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03999879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of OxPhos upregulation
Description: OxPhos upregulation \[i.e., lower phosphocreatine (PCr)-to-ATP ratio levels\] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
Study NCT02506790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT02506790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene
Study NCT02506790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Study NCT01538342 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3 Biopsies
Description: 3 biopsies: 2 lesional and 1 non-lesional
Study NCT02571842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Rituximab
Description: - 375 mg/m2 rituximab be prescribed 4 consecutive monthly
Study NCT02571842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI/ARB and corticosteroids
Description: * ACEI or ARB will be prescribed as high as tolerable dose.~* Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks
Study NCT04121130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: F-ESWT Group
Description: 3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
Study NCT04121130 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham F-ESWT
Description: 3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
Study NCT01225081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT01225081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01225081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: oral
Study NCT01225081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: oral
Study NCT03107884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Bed Rest)
Description: A clinical oral dose of Metformin will be given to participant daily during bed rest
Study NCT03107884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Bed Rest)
Description: Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
Study NCT03107884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (2 week run-in only)
Description: A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.
Study NCT03107884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2 week run-in only)
Description: Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
Study NCT04506463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-II dose I
Description: Intra-articular injection
Study NCT04506463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-II dose II
Description: Intra-articular injection
Study NCT03999879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lactate (measured with 1H-MRSI)
Description: PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
Study NCT02401581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter
Description: The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
Study NCT02918110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
Study NCT04506463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-II dose III
Description: Intra-articular injection
Study NCT04506463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection
Study NCT04615013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Not applicable to this study
Study NCT04615013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Not applicable to this study
Study NCT04615013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Not applicable to this study
Study NCT04615013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Not applicable to this study
Study NCT04615013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given IT or IN
Study NCT04615013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04615013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Not applicable to this study
Study NCT04615013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Not applicable to this study
Study NCT04615013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Not applicable to this study
Study NCT03673644 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.
Study NCT03456804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
Study NCT03349073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1101 (Tosylate)
Description: T-1101 (Tosylate) powder in bottle
Study NCT02166398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI15AML055MT
Description: tab, PO
Study NCT02166398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amosartan 5/50
Description: tab, PO
Study NCT05031195 — intervention group
Intervention type: OTHER
Intervention: 1st tertile, 2nd tertile, 3rd tertile
Description: Patients will be divided into 3 groups according to the preoperative NLR value.
Study NCT03693612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab
Description: feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.
Study NCT03693612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .
Study NCT03814733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
Study NCT03814733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
Study NCT03814733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
Study NCT03814733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rapastinel Matched Placebo
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
Study NCT03814733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alprazolam Matched Placebo
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
Study NCT03814733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine Matched Placebo
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
Study NCT02934152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H pylori eradication
Description: H pylori eradication
Study NCT02934152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H pylori eradication
Description: H pylori eradication
Study NCT02934152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H pylori eradication timing
Description: Early or late eradication
Study NCT03776955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Oral tablet
Study NCT03776955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol
Description: Oral tablet
Study NCT04969484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth visit
Description: ImPACTT Telehealth visit with the PC provider
Study NCT02599415 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TL01 light treatment
Description: Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
Study NCT01314274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 100mg intranasal submucosal bevacizumab in 10ml
Study NCT01314274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 10ml of 0.9% NaCl intranasal submucosal
Study NCT03148223 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: auriculotherapy
Description: The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
Study NCT03148223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auriculotherapy
Description: The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
Study NCT02824133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: 80 mg bd (per os)
Study NCT00439205 — intervention group
Intervention type: DEVICE
Intervention: FastEEM4 System
Description: The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
Study NCT00439205 — intervention group
Intervention type: DEVICE
Intervention: Multispectral Digital Microscope
Description: The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
Study NCT02807558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Administered as oral tablets
Study NCT01538342 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2 biopsies
Study NCT02807558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered via intravenous (IV) or subcutaneous (SC) infusion
Study NCT02807558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered via IV infusion
Study NCT03811964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Specific light exposures
Description: Specific light exposures using light in a wide range of intensities or different light/dark regimens
Study NCT00126412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-mIBG (meta-iodobenzylguanidine)
Study NCT03693612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m\^2).
Study NCT03897257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103A1 cream
Description: Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
Study NCT03897257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103A2 cream
Description: Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
Study NCT03897257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103B cream
Description: Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
Study NCT03897257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103A1B cream
Description: Investigational combination-therapy cream (containing drug A \[low dose antifungal\] + drug B \[keratolytic\]).
Study NCT03897257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103A2B cream
Description: Investigational combination-therapy cream (containing drug A \[high dose antifungal\] + drug B \[keratolytic\]).
Study NCT04348305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
Study NCT04348305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
Study NCT03256162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
Study NCT03256162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
Study NCT01618864 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Luxe
Description: Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
Study NCT02579252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AADvac1
Study NCT02579252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04189718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: osseodensification protocol
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
Study NCT04189718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseodensification protocol
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
Study NCT04189718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant site preparation protocol
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
Study NCT04189718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional implant site preparation protocol
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
Study NCT03390205 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography under dark and light adaptation
Description: Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
Study NCT02503748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online tutorial
Description: website informing about treatment options in localized prostate cancer
Study NCT01538342 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: biopsy
Description: 1 biopsy ok healthy skin
Study NCT00748007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Exelon (1.5mg/cap) 1.5 mg bid
Study NCT03693612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m\^2.
Study NCT00748007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine
Description: Exelon (1.5mg/cap) 1.5 mg bid
Study NCT02165670 — intervention group
Intervention type: DEVICE
Intervention: Coronary stenting with CE-marked stent
Study NCT04303949 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Behavioral:
Description: Facilitating couples reduce anxiety, depression and grief through e-book education.
Study NCT04303949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral:
Description: Facilitating couples reduce anxiety, depression and grief through e-book education.
Study NCT02304874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phlebotomy
Study NCT03693612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m\^2 followed by 250 mg/m\^2 once weekly.
Study NCT05522725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-use wipes installed at the bedside
Study NCT02502201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: six-minute walk study indoors
Description: Performance of a six-minute walk test according to American Thoracic Society standard.
Study NCT02502201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: six-minute walk study outdoors
Description: Performance of a six-minute walk test.
Study NCT02821338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine Extended Release
Description: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
Study NCT02257268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VAMOS program - Active life improving health
Description: All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
Study NCT01799265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somnetics Transcend Auto
Study NCT01799265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics REMstar Auto with C-Flex